Home  >  News
Msc_Apr23 .
you can get e-magazine links on WhatsApp. Click here
Patents + Font Resize -

Combined Therapeutics’ mRNA vaccine platform receives US patent

Tuesday, March 14, 2023, 14:00 Hrs  [IST]

Combined Therapeutics Inc. (CTx), a privately held biotechnology company, announced its intellectual property position reinforcement in mRNA vaccine technology with the issue of US Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7, 2023.

This patent recognizes significant innovative research and development advances by Combined Therapeutics in the mRNA vaccine field and covers its vaccine compositions which include its proprietary mRNA MOPCTx (Multi-Organ Protection) technology to deliver viral or bacterial antigens in combination with a panel of molecular adjuvants. These mRNA-expressed antigens and adjuvants together are formulated in a delivery vehicle and can be used to develop both preventive as well as therapeutic vaccines against serious infectious diseases and cancer.

"We are still only at the beginning of where our mRNA platform can take us in our efforts to further optimize global mRNA vaccine safety and efficacy," said Romain Micol, M.D., MPH, Ph.D., the company's president, chief executive officer and co-founder. "This recognition of our scientific advancements supports our development of next-generation mRNA medicines and strengthens our position as a leading innovator in vaccine technology."

As made evident by the recent pandemic, the world is increasingly in need of affordable, safe, and effective vaccines. CTx's MOP technology offers a flexible mRNA platform that can be engineered to meet specific vaccine needs and demands. This platform allows vaccine antigen expression at the site of injection, where it is needed, while restricting expression in key organs such as the heart, liver, and kidney. Additionally, when combined with a molecular adjuvant, the CTx mRNA platform enhances several critical vaccine immunogenicity parameters including extending the duration of immunity, decreasing the needed vaccine dose and improving the protection of vulnerable populations.

Combined Therapeutics Inc. (CTx) is a privately held biotechnology company developing the next generation of high value mRNA vaccines to protect everyone including vulnerable populations from global infectious diseases as well as to treat cancer.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |